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I. INTRODUCTION
The well-established rule is that pharmacists must conform
their conduct to meet the degree of care that a reasonable and
prudent person would use under similar circumstances. Courts
have described the standards for pharmacists with phrases such
* This comment is authored by Robert A. Gallagher, who received a Doctor of Phar-
macy Degree from the Mylan School of Pharmacy at Duquesne University in 2003 and
currently practices at Brooks/Eckerd Pharmacy.
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as "high degree of care" and "great care." Due to the dangerous
nature of most prescription drugs, it is no wonder that pharma-
cists must adhere to these higher standards. The pharmacist,
however, may be one of the only health care professionals required
to practice in a completely error-free manner. Those involved in
the field of pharmacy adopt a "no mistakes" approach, and prac-
tice standards reflect this impossible-to-achieve and self-imposed
standard. Despite the higher degree of care that is expected and
the self-imposed standards, courts and legislatures have been re-
luctant to expressly impose a duty to warn on pharmacists.
Traditionally, pharmacists had no duty to warn about a medica-
tion's risk.' This proposition has been supported by the thought
that the physician is the primary health care provider and the one
on whom patients rely to make the correct medical decisions for
them.2 Furthermore, some believe that the pharmacist lacks the
education, skill, training, and information required to advise the
patient properly.3 Courts and many physicians have also sup-
ported the theory that pharmacists have no duty to warn because
the pharmacist's involvement would be a direct interference with
the physician-patient relationship. 4 Others argue that requiring
the pharmacist to warn would place an undue burden on pharma-
cists because they would be forced to question every decision a
physician makes. 5
Historically, pharmacists were instructed not to tell patients
anything about the prescribed medication in order to maintain a
clear distinction between the practice of medicine and the practice
of pharmacy. 6 Since the 1950's, federal and state laws have con-
tinued to expand the practice of pharmacy beyond the rudimen-
tary tasks of counting and pouring. 7 Despite the expansion of the
practice, patients, attorneys, and pharmacists in Pennsylvania
have yet to receive a definitive legal answer as to whether phar-
1. Ingram v. Hook's Drug, 476 N.E.2d 881 (Ind. Ct. App. 1985) (holding that the duty
to warn of a drug's dangers rests with the physician and that the pharmacist has no duty to
warn); RICHARD ABOOD, PHARMACY PRACTICE AND THE LAw 324 (4th ed. 2005).
2. ABOOD, supra note 1, at 324.
3. McKee v. American Home Products, Inc., 782 P.2d 1045, 1051 (Wash. 1989).
4. Jones v. Irvin, 602 F. Supp. 399, 402 (S.D. fll. 1985).
5. ABOOD, supra note 1, at 324.
6. Id.
7. Id. The Durham-Humphrey Amendment to the Food, Drug and Cosmetic Act was
passed in 1951 and listed the information that the federal law required a pharmacist to
place on the label of a dispensed medication. Durham-Humphrey Amendment of 1951,
Pub. L. No. 215, § 578, 65 Stat. 648 (1951) (amending sections 303(c) and 503(b) of the
Federal Food, Drug, and Cosmetic Act). Interestingly, the amendment does not require
that the name of the drug be included on the label. ABOOD, supra note 1, at 324.
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macists have a duty to warn. The intent of this comment is to
show why one should assume pharmacists have an affirmative
duty to warn patients about the risks associated with their medi-
cations.
A. Overview of Topics Covered
To understand the issue of whether a pharmacist practicing in
Pennsylvania has a duty to warn the patient, one must consider a
multitude of legal, medical, and social issues. Following this in-
troduction in Part I, this comment addresses the more prominent
factors present amongst the myriad considerations that affect the
pharmacist's duty to warn. Part II discusses the learned interme-
diary doctrine; Part III outlines the history behind the duty to
warn; Part IV addresses how the legislature and courts apply the
duty to warn; and lastly, Part V of this comment evaluates where
the practice of pharmacy is headed and how the duty to warn coin-
cides with the evolution of the field of pharmacy.
B. Summary of Conclusion
Once these abovementioned items are explored, it should be-
come obvious that pharmacists in Pennsylvania have a duty to
warn. Despite the fact that no court or legislature has expressly
stated this conclusion, Pennsylvania pharmacists have self-
imposed a duty to warn. Remarkably, most practicing pharma-
cists have chosen to accept this duty without the courts or legisla-
ture forcing it upon them. This proactive approach is the impetus
for the continual expansion of the field of pharmacy. It is also the
reason why pharmacists today are such an integral part of the
health care team and are often considered America's most trusted
professionals.
II. LEARNED INTERMEDIARY DOCTRINE
Before discussing the duty to warn, it is important to analyze
the learned intermediary doctrine. For decades, patients have
relied on their physician to provide them with adequate informa-
tion and warnings concerning their prescription medications. For
centuries, the doctor has been the commander of the health care
arena. The physician has always held the ultimate power of decid-
ing what is best for his patient. Today, one rule bestows that
power on the doctor and the doctor only. That rule is known to
many as the learned intermediary doctrine. However, through
Fall 2006
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case law, legislation, practice changes, technology, and much
more, it appears that the doctrine's substance has been signifi-
cantly reduced.
The current changes in pharmacist liability have left many
questions for physicians, manufacturers, and attorneys attempt-
ing to apply the learned intermediary doctrine.8 The confusion
involves issues of whether (1) the pharmacist is a learned inter-
mediary, 9 (2) manufacturers must adequately warn pharmacists
similar to the way they inform doctors, 10 (3) the public may rely on
the pharmacist to convey needed information to them,11 and (4)
doctors and pharmacists will be able to share the role of patient
educator. 12 To share this role, physicians and pharmacists must
continue to strive for a better relationship. 13 Even though the two
professions have made monumental strides to improve and capi-
talize on their involvement with each other in patient care, tur-
moil between the two professions often surfaces. 14
A. Background
The general rule states that "drug manufacturers must warn
physicians of a drug's dangerous side effects and that the prescrib-
ing physicians have a duty to convey the warnings to their pa-
tients."15 The rule was first conceptualized in the case of Marcus
v. Specific Pharmaceuticals.16 The term "learned intermediary
doctrine" was coined nearly twenty years later in the case of Ster-
8. Diane Schmauder Kane, Annotation, Construction and Application of the Learned-
Intermediary Doctrine, 57 A.L.R.5th 1, § 4-16 (2005).
9. Id. § 19.
10. Jones v. Irvin, 602 F. Supp. 399, 402 (S.D. Ill. 1985).
11. David B. Brushwood, The Pharmacist's Legal Duty to Counsel Patients, DRUG
TOPICS, Apr. 17, 2006, at 58.
12. Johanna L. Keely, Pharmacist Scope of Practice, 136 ANN. INTERN. MED. 79, 79-85
(2002).
Pharmacists continue to successfully expand their scope of practice. With the
transition to the PharmD degree and automated drug dispensing, pharmacists
are being trained to take on a greater patient care role. Instead of taking an
adversarial position, the medical community must work together with the
pharmacy profession to enhance patient care and safety while maintaining
physician responsibility for continuous patient care.
Id. at 82.
13. Id. at 84.
14. Id.
15. Frye v. Medicare-Glaser Corp., 605 N.E.2d 557, 559 (Ill. 1992).
16. 77 N.Y.S.2d 508 (N.Y. Sup. Ct. 1948). In Marcus, the manufacturer of a supposi-
tory was not held liable for failing to warn the patient when the manufacturer had properly
warned the physicians. Marcus, 77 N.Y.S.2d at 508-09.
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ling Drug, Inc. v. Cornish. 17 The basic theory underlying the rule
is that the physician is trained to assess risks and choose the ap-
propriate therapy course for each patient.18 The rule presumes
that the physician, once made aware of the warnings involved
with a drug, will transmit any information he deems appropriate
to the patient.19 Because patients are assumed to be uneducated
in medicine, the law selects the physician instead of the patient to
receive warnings from the manufacturer. 20 The belief has always
been that direct information provided to the patient would not
adequately protect a patient who is not trained to evaluate risks.
21
Assuming that the physician was provided with the proper warn-
ing from the manufacturer, the patient who is subsequently
harmed by the medication typically has no legal recourse against
the manufacturer. 22
Prescription drugs are a unique exception to the general view
under section 402A of the Restatement (Second) of Torts. 23 Gen-
erally, a manufacturer is strictly liable for injuries caused to a
user by a product sold in a defective condition that is unreasona-
bly dangerous. 24 Section 6 of the Restatement (Third) of Torts
reiterates the learned intermediary rule that manufactures have a
duty under most circumstances to adequately warn the prescrib-
ing physician and other health care providers instead of the pa-
tient.25 Prescription drugs have long posed a difficult challenge to
American products liability law. 26 The law must constantly bal-
ance the great benefits that so many people receive from prescrip-
tion medications and the potential harm that these products may
17. 370 F.2d 82, 85 (8th Cir. 1966).
18. Ozlem A. Bordes, The Learned Intermediary Doctrine and Direct-To-Consumer
Advertising: Should the Pharmaceutical Manufacturer be Shielded from Liability?, 81 U.
DET. MERCY L. REV. 267, 286 (2004).




23. RESTATEMENT (SECOND) OF TORTS § 402A cmt. k (1965).
24. Id. § 402A.
25. RESTATEMENT (THIRD) OF TORTS § 6 cmt. d (2005). Section 6(d) states:
A prescription drug or medical device is not reasonably safe due to inadequate
instructions or warnings if reasonable instructions or warnings regarding fore-
seeable risks of harm are not provided to prescribing and other health care
providers who are in a position to reduce the risks of harm in accordance with
the instructions or warnings.
Id. § 6(d)(1).
26. Id. § 6 cmt. b.
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cause. 27 To err on the side of public safety could substantially
daunt the research and development of better and more innova-
tive medicines; however, to err in favor of manufacturers could




As the health care system continues to evolve, the limitations on
the learned intermediary doctrine continue to develop. The Re-
statement (Third) of Torts touched upon this in section 6(d)(2)
where it states that there will be times when the health care pro-
vider is not in the best position to warn the patient of the dangers
involved with a drug.29 While the American Law Institute chose
to define some of the currently recognized exceptions to the rule, it
specifically chose to defer to developing case law on what the other
exceptions may be.
30
Currently, the common law does recognize some specific excep-
tions to the learned intermediary doctrine. Some of the repeatedly
confirmed exceptions are: (1) mass immunizations; (2) oral contra-
ceptives; and (3) direct-to-consumer advertising. 31 As case law
continues to develop, the behavior of the manufacturer continues
to play an integral part in the courts' evaluation of the application
of the doctrine.
Courts have also found manufacturers to be unprotected by
learned intermediaries when they engage in activities such as
overpromotion, which results in adequate warnings becoming di-
luted, and promotion of "off label" or non-FDA approved indica-
tions. 32 While physicians at this time remain the "gatekeeper"
between patients and prescription drugs, many physicians argue
that increased advertising has significantly affected the physician-
patient relationship. 33 Others argue that imposing liability on
manufacturers for failing to warn is contrary to public policy be-
cause this will discourage research and development of new drugs
27. Timothy S. Hall, Reimagining the Learned Intermediary Rule for the New Pharma-
ceutical Marketplace, 35 SETON HALL L. REV. 193, 199 (2004).
28. Id. at 199-200.
29. RESTATEMENT (THIRD) OF TORTS § 6(d)(2) (2005).
30. Id. § 6 cmt. e. "The Institute leaves to developing case law whether exceptions to
the learned intermediary rule in these or other situations should be recognized." Id.
31. Bordes, supra note 18, at 286.
32. Martha M. Rumore, Direct-to-Consumer Advertising of Prescription Drugs: Emerg-
ing Legal and Regulatory Issues, 39 HOSP. PHARMACY 1058, 1062 (2004).
33. Id. at 1060-61.
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and increase the price of already unaffordable medications. 34
Pharmaceutical manufacturers claim that "Direct-to-Consumer
("DTC") advertising is beneficial because it works to increase pa-
tient awareness of available medications and disease states. ' 35
Attempts at increasing patient awareness have led the courts to
use other exceptions to the learned intermediary doctrine. For
example, the doctrine may not apply when the FDA requires spe-
cific information, called MedGuides, 36 to be provided to the pa-
tients upon pick-up of their prescription.31 By applying an excep-
tion in these cases, the courts are essentially relying on the FDA's
determination that for these specified medications, the physician-
patient relationship is not an effective intermediary to ensure pa-
tients receive an adequate warning.38 Because MedGuides are a
relatively new phenomenon, it remains to be determined whether
they will provide adequate warnings to the patient. One problem
that may arise is that patients are not guaranteed to receive these
guides when they pick up their medication at the pharmacy. 39
The Internet is burgeoning into another major exception to the
learned intermediary doctrine. Internet content poses the same
problem DTC advertising does. In fact, Internet sites often em-
ploy DTC advertising. Patients often go online to gain information
34. Jaclyn Casey, Prescription for Compromise: Maintaining Adequate Pharmacist Care
Contraindicates Imposition of a General Duty to Warn, 17 WASH. U. J.L. & POLY 287, 294
(2005).
35. Bordes, supra note 18, at 279.
36. MedGuides are FDA-approved patient information for selected prescription drugs
that pose a serious and significant public health concern. Effective Medication Guides Act
of 1996, Pub. L. No. 104-180, § 601, 110 Stat. 1593 (1996). MedGuides must be distributed
to patients with each new or refilled prescription by a health care provider or pharmacist
and are considered part of FDA-regulated product labeling. Id. See also MedGuides,
http://www.michiganpharmacists.org/ MedGuides.htm (last visited Sept. 5, 2006).
37. Edwards v. Basel Pharm., 116 F.3d 1341, 1342 (10th Cir. 1997). In Edwards, the
plaintiffs husband died from a nicotine overdose after applying a patch and continuing to
smoke. Edwards, 116 F.3d at 1342. The manufacturer argued that it had satisfied its duty
to directly warn the patient by warning the learned intermediary. Id. The Oklahoma
Supreme Court, answering a certified question from the Tenth Circuit, ruled that the FDA
mandate to directly warn the patient was an exception to the learned intermediary doc-
trine. Edwards v. Basel Pharm., 933 P.2d 298, 303 (Okla. 1997).
38. Hall, supra note 27, at 212-13.
39. Larry D. Sasich & Sana R. Sukkari, Don't Forget to Give Out MedGuides, DRUG
TOPICS, Apr. 3, 2006, at 52. Possible reasons why patients are not being given MedGuides
are:
(1) Pharmacists may not be aware of the MedGuide regulations; (2) pharma-
cists may believe that the written drug information they are distributing, pro-
duced by commercial vendors, meets the FDA's regulatory requirements; and
(3) the manufacturers may have failed to ensure that sufficient quantities of
the MedGuides are reaching pharmacies for distribution to patients.
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regarding a medication or disease state before seeking advice from
a doctor or pharmacist. Internet marketing and other available
information directly affects patients' beliefs about a product.
Usually, Internet sites provided by the drug manufacturers in-
clude much more detailed information than is required for televi-
sion or print advertisements. 40 There is current uncertainty in-
volving whether liability will be placed on the manufacturers for
Internet content, specifically when material is posted on third-
party sites which hyperlink to a manufacturer's sponsored site.
41
Unfortunately, the uncertainty involving liability is a common
theme that runs throughout the health care industry. With the
number of exceptions carved out of the learned intermediary doc-
trine it remains unclear what is left of the doctrine or when it is
applicable. Much of this ambiguity evolved from the advent of
modern medical science and technology. Prior to the explosion of
the pharmaceutical market, it was much simpler for the physician
to maintain adequate oversight of his patients, but now it is a
daunting challenge to stay abreast of the current products avail-
able for use. As a result, there is a constant struggle between the
patients, manufacturers, doctors and pharmacists to determine
who is or should be the "gatekeeper."
The doctor has always been considered the barrier between the
harmful effects of medicine and the patient. Through the learned
intermediary doctrine, customarily the doctor possesses the duty
to warn the patient of any potential drug interactions or adverse
events. Many believe that shifting the duty to warn to the manu-
facturer or the pharmacist would cause doctors to lose the trust of
their patients and ultimately destroy the physician-patient rela-
tionship. Others believe imposing the duty to warn on the phar-
macist would violate "public policy" because, while it would pro-
vide patients easier access to drug information, it would substan-
tially increase litigation. Both of these notions lack any substan-
tial proof and should have no bearing on whether pharmacists
have a duty to warn.
Most professionals know that by giving up liability they in turn
give up power. This is likely a primary reason why liability re-
mains centralized on the physician while other health care profes-
40. Rumore, supra note 32, at 1062-63.
41. Id. at 1063. 'The courts and legislature have not yet provided guidance on pharma-
ceutical liability pertaining to linking and framing; therefore, the threat of litigation ex-
ists." Id.
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sionals remain, for the most part, protected by the learned inter-
mediary doctrine.
A strong argument exists, however, that supports rejecting the
learned intermediary doctrine and imposing a duty to warn on the
pharmacist. The argument is premised on the pharmacist being
in the best position to communicate effectively with the patient.
Furthermore, the pharmacist possesses the skills not only to con-
vey the pertinent warnings, but also to promote patients' involve-
ment in their own therapy protocol.
III. DUTY TO WARN
Commentators and courts in favor of pharmacists having no
duty to warn generally rely on three theories: (1) the learned in-
termediary doctrine; (2) imposing a duty to warn on pharmacists
would interfere with the physician-patient relationship; and (3)
imposing a duty to warn on pharmacists would contradict "public
policy."42 While these theories have existed for some time now,
common law precedents dating back to the early nineteenth cen-
tury support the argument that pharmacists should be responsible
for more than accurately filling a prescription. 43 Under the com-
mon law, pharmacists have always been expected to perform at
the highest professional level.
44
A. Common Law
This high level of expected performance was the basis for many
pharmacist liability cases that were decided in the early twentieth
century. In Jones v. Walgreen Co., 45 the Appellate Court of Illinois
emphasized the high level of expectation placed on pharmacists to
perform their jobs competently. In Jones, the subject pharmacy
defended the claim against it by arguing, "the legal duty of a
druggist to a purchaser can go no further than to dispense the
42. Jones v. Irvin, 602 F. Supp. 399, 402 (S.D. Ill. 1985) (discussing how the imposition
of a duty to warn on pharmacists would adversely affect the physician-patient relation-
ship); Leesley v. West, 518 N.E.2d 758, 763 (111. App. Ct. 1988) (holding that the learned
intermediary rule would be violated by imposing a duty to warn on pharmacists, and that
expanding the liability of health care professionals is contrary to policy).
43. Tessymond's Case, 1 Lewin's Crown Cases 169 (1828).
44. David Brushwood, How Old Legal Precedents Produce New Rules of Law: A Case
Study of Jones v. Walgreen, 38 PHARMACY IN HISTORY 3 (1996).
45. 265 Ill. App. 308 (Ill. App. Ct. 1932).
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identical substance which his prescription calls for."46 The court
rejected this argument by stating:
[t]he instant contention is primarily based upon the assump-
tion that a pharmacist is obliged to fill any and all prescrip-
tions. Such is not the law. As a chemist he may know that
the physician has erred in his prescription and that to fill it
might cause death or serious injury to the patient. 47
The court relied heavily on precedent to reach its conclusion
that the duty of the pharmacist includes monitoring for potential
harm to the patient. 48 Each case that was cited in Jones repre-
sented the principle that pharmacists must accept responsibility
for their actions or for their failure to act. Moreover, if a pharma-
cist could possibly prevent harm to a patient and fails to do so, he
may not blame another party as being solely responsible for caus-
ing the harm. 49 The most prominent of the cases relied on in
Jones was Tremblay v. Kimball.
50
The court in Tremblay held that the law requires of a druggist
only "reasonable and ordinary" care in compounding prescriptions,
in selling medicines, and in performing the other duties of his pro-
fession; such care with reference to him means the "highest prac-
ticable degree of prudence, thoughtfulness, and vigilance," and it
is "proportioned to the danger involved."51  Furthermore, "a
breach of such duty would be negligence rendering him liable for
injuries resulting therefrom."52 The court concluded that when
the pharmacist applies his knowledge and exercises care and dili-
gence, he is bound to use his best judgment. 53 The pharmacist,
however, by using his best judgment does not absolutely guaran-
tee that no mistake will ever be committed in the execution of his
duties, and it is plausible that a qualified pharmacist may make
an error that would not be actionable negligence. 54
46. Jones, 265 Ill. App. at 320.
47. Id.
48. Id. See McGahey v. Albritton, 107 So. 751 (Ala. 1926); Martin v. Manning, 92 So.
659 (Ala. 1922); Tombari v. Connors, 85 Conn. 231 (1912); Faulkner v. Birch, 120 I1. App.
281 (1905); Tremblay v. Kimball, 77 A. 405 (Me. 1910).
49. Brushwood, supra note 11, at 58.
50. 77 A. 405 (Me. 1910).
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While the early twentieth century showed substantial reliance
upon and confidence in the field of pharmacy, this responsibility
has only recently begun to reappear in pharmacy litigation. For
several decades following the Jones decision, courts denied the
role of judgment in pharmacy, and cases were usually decided by
whether the correct medicine was placed in the bottle. It was not
until the early 1980s that the pharmacist's shield against ex-
panded liability began to crack. 55 Though the cases in the 1980s
still held that the pharmacist had no general duty to warn, they
began to cite early twentieth century cases such as Jones.
56
B. Standard of Care
Today, there appears to be a return to the prior common law,
and it is no longer enough to get the right medication, in the right
amount, to the right patient, with the right directions on the label.
Fortunately, most practicing pharmacists accept this notion and
embrace the act of counseling the patient. However, how far a
pharmacist must go in fulfilling professional and legal duties to
advise patients on the proper use of drugs remains undefined.
57
Unfortunately, as with any profession, a standard of care cannot
be easily expressed in regulations or by statute. The standard of
care for professionals is usually a culmination of tradition, expert
opinions, and court rulings. This standard of care is often sum-
marily defined as the skill and intelligence that ordinarily charac-
terizes the profession.58
Allowing professional standards to dictate when pharmacists
must warn eliminates the concept that pharmacists have no obli-
55. David Brushwood, The Pharmacist's Duty to Warn: Toward a Knowledge-Based
Model of Professional Responsibility, 40 DRAKE L. REV. 1, 1-60 (1991).
56. Jones v. Irvin, 602 F. Supp. 399 (S.D. Ill. 1985); Fakhouri v. Taylor, 618 N.E.2d 518,
520 (111. App. Ct. 1993) (citing, but rejecting, the reasoning of Jones v. Walgreen, 265 Ill.
App. Ct. 308 (1932)).
57. Docken v. Ciba-Geigy, 790 P.2d 45 (Or. Ct. App. 1990) (holding that whether a
pharmacy has a duty to warn its customers of potential risks of prescription drugs is an
issue to be answered by expert testimony as to the standard of care in the community).
58. Lasley v. Shrake's Country Club Pharmacy, 880 P.2d 1129, 1132-33 (Ariz. Ct. App.
1994). The Arizona Court of Appeals noted:
Health care providers and other professionals are held to a higher standard of
care than that of the ordinary prudent person when the alleged negligence in-
volves the defendant's area of expertise. The standard is based on "the usual
conduct of other members of the defendant's profession in similar circum-
stances." We impose this higher standard of care upon pharmacists because
they are professionals in the health care arena.




gation for safe use of medications and that any information pro-
vided should be done on a voluntary basis. It also emphasizes that
counseling patients is part of a pharmacist's required tasks. This
standard of care approach to warning the patient would certainly
be better for the profession, as well as the patients, because it po-
sitions the pharmacist as the primary source of drug advice.
IV. DUTY TO WARN CASES
Courts still generally hold that pharmacists do not have a gen-
eral duty to warn. However, courts have developed many excep-
tions to this holding, such as (1) when the pharmacist has special
knowledge regarding a patient, (2) examination of the prescription
shows that the patient will be harmed if the drug is used as pre-
scribed, (3) the pharmacist voluntarily undertakes the duty, or (4)
the pharmacist induces the public to believe counseling will be
provided. 59 Modern courts are beginning to recognize that today's
pharmacist plays a vital role in the health care system. Moreover,
these same courts hold pharmacists to a professional standard of
care.60 Under this modern approach, it is much easier for courts
to create duties and impose liability on pharmacists, including
liability for failure to warn.61
A. Pennsylvania Cases
One of the first cases in the United States to impose a duty to
warn on the pharmacist was a Pennsylvania case.6 2 Riff v. Mor-
gan Pharmacy was one of the first judicial opinions since Jones to
recognize an expanded role for pharmacists. 63 A woman was given
Cafergot® suppositories for the treatment of migraine headaches
without being told of any limit to the use of the prescription.
6 4
The doctor prescribed the suppository to be used every 4 hours
and the pharmacist typed the directions exactly as the doctor pre-
scribed. 65 The patient used them exactly as the direction on the
bottle read; however, she was not told that the suppository's use
should be limited to two suppositories per headache or five per
59. Id. at 1132.
60. Hooks SuperX, Inc. v. McLaughlin, 642 N.E.2d 514, 519 (Ind. 1994); Pittman v.
UpJohn Co., 890 S.W.2d 425, 435 (Tenn. 1994).
61. Lasley, 880 P.2d at 1132-33.
62. Riff v. Morgan Pharmacy, 508 A.2d 1247 (Pa. Super. Ct. 1986).
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week. As a result, she had a toxic reaction to the suppository and
subsequently sued both the doctor and pharmacist. 66
The pharmacy argued that it had filled the prescription in ac-
cordance with the doctor's orders, that the patient had received
the accurate medication and amount, and the pharmacy therefore
was not liable to the patient. The Superior Court of Pennsylvania
disagreed with this argument and stated that each member of the
health care team "has a duty to be, to a limited extent, his
brother's keeper."67  The court held that the pharmacy had
breached its duty to warn the patient or notify the prescribing
physician of the obvious inadequacies on the face of the prescrip-
tion that created a substantial risk of serious harm to the pa-
tient. 68 In reaching this conclusion, the court was careful to limit
this duty to notification only.69 Furthermore, the court empha-
sized that the pharmacist has no duty to assume complete control
of the patient's drug therapy. 70
While some argue that Riff opened the door for expanded legal
responsibilities, others have used Riff as a foundation to expand
the practice of pharmacy further into the realm of patient care.
After the court's ruling in Ri/f, many believed that it suggested
that pharmacists in Pennsylvania now had an absolute duty to
warn the patient. Many subsequent decisions by Pennsylvania
courts, however, have suggested otherwise.71
66. Id.
67. Id. at 1253. The court supported this notion by stating:
Fallibility is a condition of the human experience. Doctors, like other mortals,
will from time to time err through ignorance or inadvertence. An error in the
practice of medicine can be fatal; and so it is reasonable that the medical com-
munity including physicians, pharmacists, anesthesiologists, nurses and sup-
port staff have established professional standards which require vigilance not
only with respect to primary functions, but also regarding the acts and omis-
sions of the other professionals and support personnel in the health care team.
Id.
68. Riff, 508 A.2d at 1252.
69. Id.
70. Id at 1251.
71. See Mazur v. Merck & Co., 964 F.2d 1348 (3d Cir. 1992) (finding that Pennsylvania
law does not impose an independent duty to warn patients of the risks of prescription drugs
the pharmacists dispense); Ramirez v. Richardson-Merrell, Inc., 628 F. Supp. 85 (E.D. Pa.
1986) (despite expert testimony and excerpts from the "Standards of Practice for Profes-
sional Pharmacy" recommending a duty to warn, public policy and jurisprudence compel
the ruling that pharmacists are not under a general duty to warn customers of potential
adverse effects of prescription drugs); Coyle v. Richardson-Merrell, Inc., 584 A.2d 1383 (Pa.
1989) (pharmacist has no duty to warn customer regarding risks associated with a pre-
scription drug); White v. Weiner, 562 A.2d 378 (Pa. Super. Ct. 1989), affd, 583 A.2d 789
(Pa. 1991) (bulk supplier of pharmaceutical chemicals does not have the duty to warn the
final manufacturer of the prescription drug of potential risks of that chemical, citing previ-
ous courts' reluctance to extend a duty to warn to pharmacists and reiterating that the duty
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B. Other States
Like Pennsylvania, other states across the country have strug-
gled with the duty to warn issue. Most states continue to follow
the general rule that pharmacists do not have a duty to warn.
72
However, they have also started to define many circumstances
where this general rule may not apply. 73 For example, a Florida
court recently held that a pharmacist had a duty to warn patients
of the risks inherent in filling prescriptions that are not indicated
for treatment of the patient or that duplicate other medications
that the patient is already taking. 74
The Illinois Supreme Court ruled in Happel v. Wal-Mart Stores,
Inc.,75 that a pharmacy has a duty to warn a customer of a known
drug contraindication when the pharmacy is aware of both a cus-
tomer's drug allergies and that the prescribed drug is contraindi-
to warn lies with the patient's prescribing physician); Makripodis v. Merrell-Dow Pharm.,
Inc., 523 A.2d 374 (Pa. Super. Ct. 1987) (pharmacists do not have a duty to warn customers
of potential risks of prescription drugs).
72. Walls v. Alpharma USPD, Inc., 887 So.2d 881 (Ala. 2004) (learned intermediary
doctrine foreclosed any duty on the part of pharmacists to warn customers regarding risks
or potential side effects of prescription drugs); Chamblin v. K-Mart Corp., 612 S.E.2d 25
(Ga. Ct. App. 2005) (pharmacists do not have a duty to warn customers of every potential
side effect of a prescription drug); Saukas v. Walker Street Pharmacy, No. 260560, 2005
WL 1846289 (Mich. Ct. App. Aug. 4, 2005) (finding that a pharmacy which correctly filled a
valid prescription had no duty to warn of potentially harmful interactions between pre-
scribed medicines); Moore v. Mem'l Hosp. of Gulfport, 825 So.2d 658 (Miss. 2002) (holding
that a pharmacist does not have a general duty to warn); Perkins v. Windsor Hosp. Corp.,
455 A.2d 810 (Vt. 1982) (holding that a Vermont statute defining pharmacy practice does
not establish a statutory duty for pharmacists, without directly addressing a common law
duty to warn).
73. Deed v. Walgreen Co., 2004 WL 2943271 (Conn. Super. Ct. Nov. 15, 2004) (no gen-
eral duty to warn is recognized; pharmacists only have a duty to warn customers based on
the presence of certain factors, such as known contraindications, that would alert a rea-
sonably prudent pharmacist to a potential problem); Hooks SuperX, Inc. v. McLaughlin,
642 N.E.2d 514 (Ind. 1994) (duty to warn patients of adverse effects of drugs lies with the
physician, but pharmacists have a duty to cease refilling prescriptions where the customers
are using the drugs much more rapidly than prescribed); Brienze v. CVS Pharmacy, Inc.,
No. 01-1655-C, 2003 WL 23018810 (Mass. Dist. Ct. Dec. 19, 2003) (there is no general duty
to warn, but pharmacist still has a duty to warn the customer when filling multiple pre-
scriptions that were known to adversely interact with each other); In re N.Y. County Diet
Drug Litig., 691 N.Y.S.2d 501 (N.Y. App. Div. 1999) (pharmacists have no duty to warn
customers absent knowledge of customer's condition that makes the prescription drug con-
traindicated); Morgan v. Wal-Mart Stores Inc., 30 S.W.3d 455 (Tex. App. 2000) (holding
pharmacists have no general duty to warn their customers of potential adverse effects of
prescription drugs absent some special circumstances; the learned intermediary doctrine
and public policy in general weigh against imposing such a duty); Silves v. King, 970 P.2d
790 (Wash. Ct. App. 1999) (where there are no absolute contraindications regarding the
interaction of two prescription drugs, a pharmacist is under no duty to warn the customer
or notify the prescribing physician).
74. Powers v. Thobani, 903 So.2d 275 (Fla. Dist. Ct. App. 2005).
75. 766 N.E.2d 1118 (Ill. 2002).
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cated for a person with those allergies. 76 By imposing this duty to
warn on pharmacists, the court rejected the applicability of the
learned intermediary doctrine in this factual situation. 77 Instead
of applying the learned intermediary doctrine in Happel, the court
reasoned that the doctrine is inapplicable when the pharmacy
possesses both patient-specific medical information and knowledge
of a contraindication.
78
In determining whether such a duty existed, the Illinois Su-
preme Court looked to several factors, including: "(1) the reason-
able foreseeability that the defendant's conduct may injure an-
other, (2) the likelihood of an injury occurring, (3) the magnitude
of the burden of guarding against such injury, and (4) the conse-
quences of placing that burden on the defendant." 79 In applying
these factors, the court held that because the pharmacy knew of
both Happel's allergy and the medication's contraindication, it was
foreseeable that failing to warn Happel or her doctor of the contra-
indication could result in injury or death.80 Moreover, the court
reasoned that imposing a duty to warn on pharmacists recognizes
that pharmacists often have a better opportunity to reduce medi-
cation-based risks.8
1
Similarly, Tennessee courts have held that a pharmacist has a
duty to warn.8 2 In Pittman v. Upjohn Co., the Supreme Court of
Tennessee held that the subject pharmacy had a duty to warn
based on standards of practice.8 3 The court noted that other
pharmacies regularly made warnings when dispensing the same
product. 84 Additionally, in reaching its conclusion the court relied
on the fact that the pharmacist was aware that the customer had
not received a warning from her physician.85
Because of the ambiguity in the case law in the Commonwealth
and the other states throughout the country, it is clear that a
Pennsylvania pharmacist may no longer rely on the general rule
76. Happel, 766 N.E.2d at 1120.
77. Id. at 1130.
78. Id.
79. Id. at 1123-24.
80. Id. at 1124.
81. Happel, 766 N.E.2d at 1124.
82. Pittman v. UpJohn Co., 890 S.W.2d 425 (Tenn. 1994). See also Dooley v. Everett,
805 S.W.2d 380 (Tenn. Ct. App. 1990) (issue of whether pharmacist had a duty to warn
customer of potential drug interactions is a question of fact to be determined by a jury;
pharmacists are judged according to the standard of care required by their profession).
83. Pittman, 890 S.W.2d 425.




that there is no duty to warn. Federal case law fails to clarify the
instant matter. The cases available only serve to further blur the
issue. As a result, a pharmacist in Pennsylvania should not prac-
tice under the premise that there is no duty to warn patients.
C. Federal Cases
The regulation of pharmacy practice is generally a power re-
served to the states. The federal cases construing state law in-
volving duty to warn issues, therefore, mirror the holdings found
in many state cases. Unfortunately, because of the contradictory
case law across the country, federal law fails to provide additional
guidance to the issue at hand. Similar to the majority of states,
the United States Court of Appeals for the Fifth Circuit, constru-
ing Texas law, has held that pharmacists do not have a duty to
warn customers in Texas when physicians prescribe the wrong
medicine.86 Moreover, federal courts have mirrored most states in
holding that pharmacists voluntarily assume the duty to warn
when they advertise to customers about special drug utilization
review services.8 7 While federal cases may not provide the re-
quired assistance to determine the duties and liabilities of phar-
macists in Pennsylvania, federal legislation may shed some light
on the issue. As the pharmacy profession gains recognition and
attention in the courts, the federal government has continued to
place more emphasis on the role of the pharmacist, as is evident
from recently implemented federal legislation.
V. IMPACT OF GOVERNMENT
Over the past twenty years, litigation involving the pharma-
cist's duties to warn and counsel has significantly increased. As
explained below, the federal government has responded by includ-
ing practice guidelines for pharmacies in Federal Medicare and
Medicaid assistance legislation. In the early 1990s, Congress be-
gan to recognize the improvement in care resulting from pharma-
cist consultation. As a result, it required all states to implement
counseling requirements in order to receive funding for Medicaid
patient prescriptions. This statute is referred to commonly as
OBRA-90. More recently, Congress implemented the Medicare
86. Wimm v. Jack Eckerd Corp., 3 F.3d 137 (5th Cir. 1993).
87. Shampaine v. Bayer Corp., No. 02-1422, 2003 WL 22023391 (D. Minn. Feb 26,
2003).
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Part D program that was the first prescription drug coverage pro-
gram made available for all Medicare recipients. External influ-
ences such as the OBRA-90 and Medicare Part D have forced at-
torneys and judges to rethink the traditional role of the pharma-
cist.
A. OBRA-90
The United States Congress expanded, both indirectly and di-
rectly, the duty of pharmacists through its enactment of drug use
review provisions in the Omnibus Budget Reconciliation Act of
1990.88 The purpose of OBRA-90 is, in part, to "enhance the role
of pharmacists in providing quality medical care, through a com-
prehensive drug utilization review program."8 9 Under OBRA-90,
the pharmacist is required to discuss with each person who pre-
sents a prescription matters that are significant in the pharma-
cist's professional judgment, such as special directions and pre-
cautions for preparing, administering and using the drug, common
severe or adverse effects or interactions, and contraindications. 90
The pharmacist must also make a reasonable effort to obtain a
record and maintain the patient's history, including known aller-
gies, drug reactions and the medications taken. 91
Although OBRA-90 only applies to Medicaid patients, many
commentators and courts see it as establishing a minimum stan-
dard of care for pharmacists. 92 Furthermore, many states, includ-
ing Pennsylvania, require pharmacists to undertake drug review
activities for all drugs dispensed. In these states, pharmacists
must offer counseling, similar to what is required under OBRA-90,
to all patients. 93
At least one jurisdiction has imposed greater duties on pharma-
cists based upon a statute enacted after OBRA-90. Based on a
variety of factors, the Supreme Court of Tennessee held that a
88. David B. Brushwood, The Pharmacist's Duty Under OBRA-90 Standards, 18 J.
LEGAL MED. 475, 476 (1997). The provisions of OBRA-90 relating to drug use review are
contained in Pub. L. No. 101-508 section 4401 (Nov. 5, 1990), and are codified at 42 U.S.C. §
1396r-S(g) (1991). Id.
89. 42 U.S.C. § 1396r-8.
90. Id. § 1396r-8(g)(2)(a)(ii).
91. Id.
92. Brushwood, supra note 88, at 485.
93. 42 U.S.C. § 1396r-8(g). Pharmacists must provide counseling for their customers
about matters that in their professional judgment, are important, including: dosage and
drug administration; precautions, side effects, adverse effects and interactions; and proper
storage and refill information. Id.
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pharmacist has a duty to warn patients of the dangers of the pre-
scription drug dispensed by the pharmacist. 94 The court ex-
plained that although the standards promulgated by the state
board of pharmacy pursuant to OBRA-90 did not establish the
duty owed by a pharmacist, they provided guidance in determin-
ing that duty.95 The court concluded that the pharmacist had a
duty to warn the customer about the dangers of the prescription
drug at issue, especially when the pharmacist knew that the phy-
sician had not warned the patient about the drug.
96
B. Medicare Part D
In general, Medicare Part D provides prescription drug benefits
to everyone who is enrolled in Medicare, regardless of their income
or the source of their health care or drug coverage. 97 Medicare
Part D substantially affects a great number of Americans, and the
federal government chose to utilize the pharmacist to obtain im-
proved therapeutic outcomes for these many Americans. Under
the Medicare Part D provisions, prescription drug plans are re-
quired to provide Medication Therapy Management ('MTM") ser-
vices for "targeted beneficiaries" who have multiple chronic dis-
eases, multiple medications, and are likely to incur costs above a
certain level.9
8
MTM services are to be provided by health care professionals,
such as pharmacists, and the services are to encompass a broad
range of professional activities and responsibilities within the li-
censed pharmacist's scope of practice. 99 The services include pa-
tient-specific and individualized services provided directly by a
pharmacist to the patient. For providing the services, the phar-
94. Pittman v. Upjohn Co., 890 S.W.2d 425 (Tenn. 1994).
95. Pittman, 890 S.W.2d 425.
96. Id. at 435.
97. On December 8, 2003, President George W. Bush signed into law Public Law 108-
173, the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003.
This new law amended section 1144 of the Social Security Act to require the Commissioner
of Social Security to conduct additional outreach efforts to identify individuals entitled to
benefits, or enrolled under the Medicare program under Title XVIII, who may be eligible for
transitional assistance under the Medicare Prescription Drug Discount Card Program and
premium and cost-sharing subsidies under the Prescription Drug Card Part D Program.
Medicare Prescription Drug, Improvement, and Modernization ACT (MMA) of 2003, Pub. L.
No. 108-173, 117 Stat. 2066 (2003).
98. Id. See also Centers for Medicare and Medicaid Services,
http://www.cms.hhs.gov/Medicare (last visited Oct. 12, 2006).
99. American Pharmacists Association,
http://www.aphanet.org/AM/Template.cfm?Section+/CMlContentDisplay.cfm (last visited
Oct. 12, 2006). 1
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macist will receive payment based on time, clinical intensity, and
resources required to provide the services. The liability poten-
tially involved with providing these services has yet to be deter-
mined. As pharmacists in Pennsylvania begin to provide these
services they must be mindful of the duty to warn. Even courts
following the no duty to warn tradition may find pharmacists pro-
viding these services to have expanded duties. Furthermore, the
Pennsylvania State Board of Pharmacy 00 will likely set forth
guidelines that will help define the expected standards of practice.
C. Current Pennsylvania Law
States regulate not only who may practice pharmacy and where
it may be practiced, but also how pharmacy is practiced. Even
though a state has promulgated a mandatory patient counseling
regulation, a pharmacist will not necessarily be held civilly liable
for failing to counsel patients. 10 1 In Pennsylvania, the State
Board of Pharmacy determines the standards of pharmacy prac-
tice. The counseling laws that Pennsylvania enacted following the
mandate of OBRA-90 require records that indicate the type of care
provided by a pharmacist. Under the State Board of Pharmacy
Standards, a pharmacist must conduct a Prospective Drug Review
("PDR") and offer patient counseling with each new prescrip-
tion. 10
2
The PDR requires that the pharmacist review a patient's profile
maintained in the pharmacy prior to dispensing medication to the
patient. 0 3 The offer to counsel must be made to each patient or
caregiver when the pharmacist fills, delivers or sends a new retail
or outpatient prescription. 10 4 If the patient or caregiver accepts
100. The State Board of Pharmacy regulates the practice of pharmacy in Pennsylvania.
The Board registers pharmacy interns and licenses pharmacists and pharmacies. The
Board is charged with passing upon initial qualifications for licensure and with imposing
sanctions against persons and businesses who violate the Pharmacy Act. The Board's regu-
lations govern practice standards, drug storage, and security and dispensing requirements;
facility requirements, licensure requirements, internships, and continuing education. State
Board of Pharmacy, http://www.dos.state.pa.us/bpoa/cwp/view.asp?a=1104&q=432995 (last
visited Oct. 12, 2006). See also 49 PA. CODE § 27 (2006).
101. Nichols v. Cent. Merch., 817 P.2d 1131 (Kan. Ct. App. 1991).
102. 49 PA. CODE § 27.19(b).
103. Id. The pharmacist should make a reasonable effort to obtain, record and maintain
the following information about each patient: (i) the name, address, telephone number, date
of birth and gender; (ii) individual history, if significant, including known allergies and
drug reactions, and a list of medications and relevant devices, as provided by the patient or
caregiver; and (iii) pharmacist comments relative to the individual's therapy. Id. § 27.19(g).
104. Id. § 27.19(e). The following are examples of matters which a pharmacist in the
exercise of professional judgment might deem significant and discuss with the patient or
Fall 2006
Duquesne Law Review
counseling, the pharmacist is the only person who may provide
counseling, and if the offer to counsel is rejected it must be docu-
mented and maintained for at least two years. Thus, during in-
spection, a state inspector can easily learn whether a patient was
counseled and what information was conveyed to the patient. If
there is no record that the pharmacist counseled the patient or
made any recommendation to the doctor, it is assumed he failed to
meet the standard of care.
Since the enactment of Pennsylvania's state counseling laws,
most pharmacies have conformed their conduct to meet these re-
quirements. It is yet to be determined, however, whether these
counseling laws have created a standard of practice that the
courts will use to find a duty to warn. In Ramirez v. Richardson-
Merrell, Inc.,10 5 the United States District Court for the Eastern
District of Pennsylvania, applying Pennsylvania law, held that
despite expert testimony and excerpts from the "Standards of
Practice for Professional Pharmacy" recommending a duty to
warn, public policy and jurisprudence compelled the ruling that
pharmacists are not under a general duty to warn customers of
potential adverse effects of prescription drugs.10 6 Although a ma-
jority of courts reject the notion that state counseling laws create a
duty to warn, a minority of courts point to counseling laws as evi-
dence that pharmacists have a duty to warn. 107
VI. THE PHARMACY PRACTICE
A. Assuming the Duty to Warn
Liability may also be based upon the pharmacist's voluntary as-
sumption of a duty. A pharmacy, like any other person or entity,
may voluntarily assume a duty that would not otherwise be im-
posed on it, and thus may voluntarily assume a duty to provide
caregiver: (i) the name and description of the medication; (ii) the route of administration,
dosage form and duration of drug therapy; (iii) special directions and precautions for prepa-
ration, administration and use by the patient; (iv) common severe side effects or interac-
tions and therapeutic contraindications that may be encountered, including how to avoid
them, and the action required if they occur; (v) techniques for self-monitoring drug therapy;
(vi) proper storage; (vii) prescription refill information; and (viii) action to be taken in the
event of a missed dose. Id.
105. 628 F.Supp. 85 (E.D. Pa. 1986).
106. Ramirez, 628 F.Supp. 85.
107. See e.g., Presto v. Sandoz Pharm. Corp., 487 S.E.2d 70 (Ga. Ct. App. 1997) (prior to
the implementation of Board of Pharmacy regulations requiring pharmacists to counsel
patients, pharmacists had no duty to warn about side effects associated with discontinued
use of a prescription drug).
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information, advice, or warnings to patients. 08 Following this
logic, one can conclude that most pharmacists already have a duty
to warn. Rare are the pharmacies that do not offer screening for
drug interactions or contraindications. Most pharmacies today
are equipped with intricate software programs that provide auto-
matic screening of each patient's profile. Every prescription en-
tered into the system is crosschecked against the patient's aller-
gies, disease states, and other medications. With technology such
as this in place, it is hard to imagine how pharmacies have not
already assumed the duty to warn patients. 10 9 States that have
been faced with cases where a pharmacist has advertised services
or utilized these computer systems have consistently ruled that
the pharmacist assumed the duty to warn.110 In addition to new
technology, other advancements may also indicate assumption of a
duty. For example, the decision to implement heightened educa-
tion requirements for pharmacists may induce a court to raise its
expectations regarding the duties of a pharmacist.
B. The Doctor of Pharmacy Degree and Pharmacists'Enhanced
Abilities
In a study conducted prior to the countrywide shift to the Doctor
of Pharmacy degree, approximately one third of the pharmacists
tested were unaware of the seriousness of the interacting combi-
nations present in the study."' Studies such as this indicated
that the pharmacy profession as a whole was not ready to assume
the duty to warn. In the late 1990s, most pharmacy schools across
the country switched to the mandatory Doctor of Pharmacy
("PharmD") degree program. The PharmD degree has added a
108. Cottam v. CVS Pharmacy, 764 N.E.2d 814 (Mass. 2002).
109. David B. Brushwood & Carole L. Kimberlin, Voluntary Undertaking Rule and Duty
to Warn, 59 AM. J. HEALTH-SYST PHARM. 1867 (2002).
110. Sanderson v. Eckerd Corp., 780 So.2d 930 (Fla. Dist. Ct. App. 2001) (pharmacy that
advertised a promise that its computer system would detect and warn customers of adverse
drug reactions and interactions voluntarily assumed a duty to warn, the scope of which was
measured by the level of care and skill which, in light of all relevant circumstances, is rec-
ognized as acceptable and appropriate by other reasonably prudent pharmacists); Baker v.
Arbor Drugs, Inc., 544 N.W.2d 727 (Mich. Ct. App. 1996) (a pharmacy, which implemented
and advertised a computer system designed to detect harmful drug interactions, voluntarily
assumed a duty to operate the system with due care); Ferguson v. Williams, 374 S.E.2d 438
(N.C. Ct. App. 1988), appeal after remand, 399 S.E.2d 389 (N.C. Ct. App. 1991) (holding
even though a pharmacist has no general duty to warn a customer about potential risks, a
pharmacist who undertakes to advise a client concerning a medication has a duty to give
correct advice).
111. Rick A. Weidman et al., Pharmacist Recognition of Potential Drug Interactions, 56
AM. J. HEALTH-SYST PHARM. 1524 (1999).
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substantial amount of clinical and practical experience to the
course load. Today's graduating students spend countless credit
hours reviewing drug interactions, contraindications, suboptimal
therapy, missed opportunities, side effects, and much more. This
substantial increase in training that a graduating student receives
will surely influence both the boards of pharmacy and the courts
to continue to place more responsibility on the pharmacist. Natu-
rally, the duty to warn comes with this increased responsibility.
C. Expansion of Pharmacy
As the practice of pharmacy continues to expand, so too will the
evolution of the clinical pharmacist. Historically, clinical phar-
macy 112 was centered on the pharmacist ensuring that the patient
was aware of the doctor's orders and was adhering to them. To-
day, the clinical pharmacist provides services well beyond just
warning patients and ensuring that they heed their doctor's ad-
vice. The clinical practitioners interview patients and explain the
importance of drug therapy. They also work with physicians dur-
ing rounds and help make decisions on therapeutic alternatives. 11 3
This increased collaboration with doctors and involvement with
patients has produced a new approach to pharmacy practice
known as pharmaceutical care.
D. Pharmaceutical Care
The pharmaceutical care model includes pharmacists that en-
courage patients to assume responsibility for drug therapy within
the framework of their own lifestyles, values, and environmental
factors." 4 This model represents a shift in pharmacy practice to
focusing on the patient's needs instead of only the doctor's orders.
Pharmacists and doctors alike have embraced pharmaceutical
care, and it has given way to substantial improvements in patient
outcomes. With this newfound autonomy, a career as a pharma-
112. Clinical Pharmacy is a commonly used term in pharmacy practice and literature. It
is a health specialty, which describes the activities and services of the clinical pharmacist
to develop and promote the rational and appropriate use of medicinal products and devices.
Clinical Pharmacy includes all the services performed by pharmacists practicing in hospi-
tals, community pharmacies, nursing homes, home-based care services, clinics and any
other setting where medicines are prescribed and used. The American Pharmacy Associa-
tion, Definition of Clinical Pharmacy as a Specialty in Clinical Practice, 19(2) THE ANNALS
OF PHARMACOTHERAPY 149, 149-50 (1985).
113. ABOOD, supra note 1, at 324.
114. Id.
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cist is becoming more exciting, more fulfilling, and more challeng-
ing than ever before. However, with this autonomy there must
also be responsibility, which in turn, gives rise to liability. As
courts continue to recognize the importance of the pharmacist,
they will continue to increase the pharmacist's exposure to liabil-
ity. As this occurs in Pennsylvania, it is important that pharma-
cists view the increase in liability as an opportunity to better serve
their patients, rather than a restriction on their ability to do their
job free from limitations.
For example, some of the pharmacy-related programs currently
being implemented or considered by independent, chain, and hos-
pital pharmacists in Pennsylvania are the following: (1) Medica-
tion Therapy Management under Medicare Part D; (2) pharmacist
immunization certifications and clinics; (3) pharmacist oversight
of the distribution of Psuedoephendrine and emergency contracep-
tives; (4) "Ask the Pharmacist" or "Brown-Bag" programs; (5)
pharmacies with in-house nurse practitioners available to see pa-
tients; and (6) potential prescribing rights for pharmacists. These
programs are an indication of the expanding role the pharmacist
is establishing in health care. If pharmacists wish to continue to
participate in programs such as these and implement others, they
must be willing to accept the increase in liability that will prove
beneficial to both the public and the profession of pharmacy.
E. Improvements for Pharmacy Practice
Imposing a duty to warn on pharmacists in Pennsylvania will
continually improve patient involvement in their treatment and
the outcomes that they receive. This progressive improvement
may potentially lead to monumental advancements in the field of
pharmacy. For example, "fee for service" programs may actually
become a reality that will ultimately increase, not only pharmacy
pay, but also job satisfaction. Moreover, the duty to warn will ul-
timately increase patient counseling, and that would lead to the
reduction in monotonous job tasks that pharmacists often criticize.
VII. CONCLUSION
As pharmacies continue to expand their services and pharma-
cists continue to further their education, it is unlikely that courts
in this Commonwealth will continue to find no duty to warn. Re-
gardless of the learned intermediary doctrine, the physician-
patient relationship, and "public policy," pharmacists in Pennsyl-
vania must remain mindful of the duty to warn. Despite the con-
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trary case law in Pennsylvania and in most states throughout the
country, no pharmacist should continue to practice under the
premise that he has no duty to warn patients about their prescrip-
tion medications. Put simply, the practice of pharmacy is growing
at an exponential rate, and it will take some time for legislatures
and courts to catch up; but when the law does, pharmacists must
be prepared to accept this liability, and attorneys must be ready to
advise them. Fortunately, most pharmacists throughout the Com-
monwealth are already ahead of the law and will continue to in-
clude meaningful patient consultations in their job description.
Despite immense pressure to practice error free in a highly time-
sensitive fashion, Pennsylvania pharmacists must continue to
maintain the highest standards possible in regards to warning
patients. Practicing beyond the requirements of current case law
will help to ensure that the pharmacist remains one of the most
respected and trusted professionals in this Commonwealth and
throughout the country.
Robert A. Gallagher
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